Despite widespread efforts to improve education and enhance public awareness, up to 33% of persons with hypertension remain undiagnosed, and only about 50% of those known to have hypertension are adequately controlled. The percentages of patients who are aware that they have hypertension, who are treated, and who are controlled have increased since the 1970s (Table 75.1). Most have stage 1 hypertension, and controversy still exists concerning the appropriate approach to these patients. Nonpharmacologic therapy is often the first choice, and this approach continues to evolve.1 Of the 20 million to 30 million hypertensives who receive pharmacologic therapy, fewer than 50% adhere to their therapeutic regimen for more than 1 year, and 60% of these patients reduce the dosage of their drug owing to adverse effects. A negative impact on the patient’s quality of life may occur as a result of just making the diagnosis.
KeywordsPeripheral Vascular Disease Adverse Effect Profile Joint National Committee Angiotensin Receptor Antagonist Intrinsic Sympathomimetic Activity
Unable to display preview. Download preview PDF.
- 1.National Institutes of Health. Fifth Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. National High Blood Pressure Education. Bethesda: National Heart, Lung and Blood Institute, 1993. NIH Publication No. 93–1088.Google Scholar
- 11.Patel C, Marmot MG. Stress management, blood pressure and quality of life. J Hypertens 1987;5 Suppl 1:521–8.Google Scholar
- 13.American Hospital Formulary Service Drug Information. Bethesda: American Society of Hospital Pharmacists, 1990.Google Scholar
- 14.Kaplan NM. Clinical hypertension. 5th ed. Baltimore: Williams & Wilkins, 1993.Google Scholar
- 16.Merck and Co. Cozaar monograph. Rahway, NJ: Merck, April 1995.Google Scholar